Personalized Network‐Based Treatments in Oncology

[1]  U. Nielsen,et al.  Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors , 2013, Science Signaling.

[2]  F. Nicolantonio,et al.  Liquid biopsy: monitoring cancer-genetics in the blood , 2013, Nature Reviews Clinical Oncology.

[3]  Jorge S. Reis-Filho,et al.  Circulating tumour cells and cell-free DNA as tools for managing breast cancer , 2013, Nature Reviews Clinical Oncology.

[4]  Krishnendu Chatterjee,et al.  Evolutionary dynamics of cancer in response to targeted combination therapy , 2013, eLife.

[5]  Tian Xia,et al.  Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. , 2013, ACS nano.

[6]  Rune Linding,et al.  Navigating cancer network attractors for tumor-specific therapy , 2012, Nature Biotechnology.

[7]  Karen Sachs,et al.  Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators , 2012, Nature Biotechnology.

[8]  Liang Liu,et al.  Network-based drug discovery by integrating systems biology and computational technologies , 2012, Briefings Bioinform..

[9]  B. Al-Lazikani,et al.  Combinatorial drug therapy for cancer in the post-genomic era , 2012, Nature Biotechnology.

[10]  H. Hieronymus,et al.  Traversing the genomic landscape of prostate cancer from diagnosis to death , 2012, Nature Genetics.

[11]  R. Linding,et al.  Network Medicine Strikes a Blow against Breast Cancer , 2012, Cell.

[12]  P. Sorger,et al.  Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks , 2012, Cell.

[13]  A. Kesselheim,et al.  The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs , 2012, PloS one.

[14]  J. Burnett,et al.  RNA-based therapeutics: current progress and future prospects. , 2012, Chemistry & biology.

[15]  Jörn Lötsch,et al.  Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects. , 2011, Drug discovery today.

[16]  Mindy I. Davis,et al.  Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.

[17]  Theonie Anastassiadis,et al.  Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity , 2011, Nature Biotechnology.

[18]  Bissan Al-Lazikani,et al.  canSAR: an integrated cancer public translational research and drug discovery resource , 2011, Nucleic Acids Res..

[19]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[20]  Jorge S Reis-Filho,et al.  Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction , 2011, Breast Cancer Research.

[21]  Michael R Stratton,et al.  Genomics and the continuum of cancer care. , 2011, The New England journal of medicine.

[22]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[23]  Brian D Ross,et al.  Predicting and monitoring cancer treatment response with diffusion‐weighted MRI , 2010, Journal of magnetic resonance imaging : JMRI.

[24]  G. Mills,et al.  Future of personalized medicine in oncology: a systems biology approach. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Linding,et al.  Simplistic pathways or complex networks? , 2010, Current opinion in genetics & development.

[26]  Jorge S Reis-Filho,et al.  The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade , 2010, The Journal of pathology.

[27]  R. Linding,et al.  Network‐based drugs and biomarkers , 2010, The Journal of pathology.

[28]  Tony Pawson,et al.  Cell-Specific Information Processing in Segregating Populations of Eph Receptor Ephrin–Expressing Cells , 2009, Science.

[29]  Andrew L. Hopkins,et al.  Drug discovery: Predicting promiscuity , 2009, Nature.

[30]  Forest M White,et al.  Oncogenic EGFR Signaling Networks in Glioma , 2009, Science Signaling.

[31]  V. Grantcharova,et al.  Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis , 2009, Science Signaling.

[32]  Michael J. Emanuele,et al.  A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.

[33]  Norbert Avril,et al.  Response to Therapy in Breast Cancer , 2009, Journal of Nuclear Medicine.

[34]  Angelo D. Favia,et al.  Protein promiscuity and its implications for biotechnology , 2009, Nature Biotechnology.

[35]  Daniel G. Anderson,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[36]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[37]  C. Bakal,et al.  Phosphorylation Networks Regulating JNK Activity in Diverse Genetic Backgrounds , 2008, Science.

[38]  R. Bernards,et al.  Enabling personalized cancer medicine through analysis of gene-expression patterns , 2008, Nature.

[39]  Forest M White,et al.  Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma , 2007, Proceedings of the National Academy of Sciences.

[40]  A. Barabasi,et al.  Network medicine--from obesity to the "diseasome". , 2007, The New England journal of medicine.

[41]  P. Bork,et al.  Systematic Discovery of In Vivo Phosphorylation Networks , 2007, Cell.

[42]  C. Bakal,et al.  Quantitative Morphological Signatures Define Local Signaling Networks Regulating Cell Morphology , 2007, Science.

[43]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[44]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[45]  John P. Overington,et al.  Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.

[46]  D. Lauffenburger,et al.  A Systems Model of Signaling Identifies a Molecular Basis Set for Cytokine-Induced Apoptosis , 2005, Science.

[47]  R C Young,et al.  Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer , 1975, Cancer.

[48]  N. Gulbahce,et al.  Network medicine: a network-based approach to human disease , 2010, Nature Reviews Genetics.

[49]  T. Pawson,et al.  Network medicine , 2008, FEBS letters.

[50]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.